EHA 2016 - European Hematology Association - June 9-12, 2016
Chronic Myeloid Leukemia - CML -21th Congress of EHA
VIDEO
Modelling ponatinib resistance in BCR-ABL1 cell line s (Dr. Liu Lu, Australia)
August 3, 2016, ecancer
Modelling ponatinib resistance in BCR-ABL1 cell line s (Dr. Liu Lu, Australia)
August 3, 2016, ecancer
SOME INTERESTING ABSTRACTS FOR CML
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Results from Enestfreedom: treatment-free remission (TFR) following frontline Nilotinib (NIL) in patients (PTS) with chronic myeloid leukemia (CML-CP)
Factors that influence patient willingness to attempt treatment-free remission in chronic myeloid leukemia
Efficacy and safety of imatinib generics; a report from polish(palg)imatinib generics registry
Efficacy and safety of first-line treatment with nilotinib in elderly chronic myeloid leukemia patients
Landmark analyses in the pivotal ponatinib pace trial: impact of early responses on 3 year outcomes in heavily pretreated cp-cml patients
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukaemia
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Results from Enestfreedom: treatment-free remission (TFR) following frontline Nilotinib (NIL) in patients (PTS) with chronic myeloid leukemia (CML-CP)
Factors that influence patient willingness to attempt treatment-free remission in chronic myeloid leukemia
Efficacy and safety of imatinib generics; a report from polish(palg)imatinib generics registry
Efficacy and safety of first-line treatment with nilotinib in elderly chronic myeloid leukemia patients
Landmark analyses in the pivotal ponatinib pace trial: impact of early responses on 3 year outcomes in heavily pretreated cp-cml patients
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukaemia
